よむ、つかう、まなぶ。
08 参考資料1－2 沈降ヘモフィルスｂ型ワクチンファクトシート［2.4MB］ (34 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_34803.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第20回 8／29）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
38.
Townsend K, Ladhani SN, Findlow H, Borrow R. 2014. Evaluation and
validation of a serum bactericidal antibody assay for Haemophilus
influenzae type b and the threshold of protection. Vaccine 32:5650-5656
39.
Togashi T, Mitsuya N, Kogawara O, Sumino S, Takanami Y, and Sugizaki K.
2016. Immunogenicity and safety of a fully liquid aluminum phosphate
adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in
healthy Japanese children: A phase Ⅲ, randomized, observer-blind,
multicenter, parallel-group study. Vaccine
doi:10.1016/j.vaccine.2016.05.050
40.
Jun L, Yuguo C, Zhiguo W, Jinfeng L, Huawei M, Xiuhua L, et al. 2013.
Assessment of immunogenicity and safety following primary and booster
immunisation with a CRM197 -conjugated Haemophilus influenzae type b vaccine
in healthy Chinese infants. Int J Clin Pract 67:971-978
41.
Kanra G, Viviani S, Yurdakok K, Ozmert E, Anemona A, Yalcin S, et al. 2003.
Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus
influenzae type b-CRM197 conjugate vaccine. Pediatr Int 45:314-318
42.
Pancharoen C, Mekmullica J, Thisyakorn U, Bianchini M. 2004. A phase IV
open label study to assess the safety, tolerability and immunogenicity of
a Haemophilus influenzae type b (Hib) CRM197 conjugated vaccine administered
to healthy infants at 2, 4, and 6 months of age. Southeast Asian J Trop
Med Public Health 35:927-929
43.
Matjila MJ, Phohu TC, Banzhoff A, Viviani S, Hoosen AA, Bianchini M, et
al. 2004. Safety and immunogenicity of two Haemophilus influenzae type b
conjugate vaccines. S Afr Med J 94:43-46
44.
Romero-Steiner S, Fernandez J, Biltoft C, Wohl ME, Sanchez J, Feris J, et
al. 2001. Functional antibody activity elicited by fractional doses of
Haemophilus influenzae type b conjugate vaccine (polyribosylribitol
phosphate-tetanus toxoid conjugate). Clin Diagn Lab Immunol 8:1115-1119
45.
古泉ゆか, 服部裕美, 明田幸宏, 矢野秀美, 石和田稔彦, 一ノ瀬昭豊, et al.
2013. Hibワクチンによる免疫誘導能の評価とその臨床的意義：Hib vaccine
failure 例の解析. 病原微生物検出情報 (IASR) 34: 190-191
46.
武田薬品工業. 2014. 健康乳幼児におけるTAK-816の有効性及び安全性を検討
するアクトヒブを対照とした第Ⅲ相多施設共同無作為化二重盲検並行群間比較
31
Townsend K, Ladhani SN, Findlow H, Borrow R. 2014. Evaluation and
validation of a serum bactericidal antibody assay for Haemophilus
influenzae type b and the threshold of protection. Vaccine 32:5650-5656
39.
Togashi T, Mitsuya N, Kogawara O, Sumino S, Takanami Y, and Sugizaki K.
2016. Immunogenicity and safety of a fully liquid aluminum phosphate
adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in
healthy Japanese children: A phase Ⅲ, randomized, observer-blind,
multicenter, parallel-group study. Vaccine
doi:10.1016/j.vaccine.2016.05.050
40.
Jun L, Yuguo C, Zhiguo W, Jinfeng L, Huawei M, Xiuhua L, et al. 2013.
Assessment of immunogenicity and safety following primary and booster
immunisation with a CRM197 -conjugated Haemophilus influenzae type b vaccine
in healthy Chinese infants. Int J Clin Pract 67:971-978
41.
Kanra G, Viviani S, Yurdakok K, Ozmert E, Anemona A, Yalcin S, et al. 2003.
Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus
influenzae type b-CRM197 conjugate vaccine. Pediatr Int 45:314-318
42.
Pancharoen C, Mekmullica J, Thisyakorn U, Bianchini M. 2004. A phase IV
open label study to assess the safety, tolerability and immunogenicity of
a Haemophilus influenzae type b (Hib) CRM197 conjugated vaccine administered
to healthy infants at 2, 4, and 6 months of age. Southeast Asian J Trop
Med Public Health 35:927-929
43.
Matjila MJ, Phohu TC, Banzhoff A, Viviani S, Hoosen AA, Bianchini M, et
al. 2004. Safety and immunogenicity of two Haemophilus influenzae type b
conjugate vaccines. S Afr Med J 94:43-46
44.
Romero-Steiner S, Fernandez J, Biltoft C, Wohl ME, Sanchez J, Feris J, et
al. 2001. Functional antibody activity elicited by fractional doses of
Haemophilus influenzae type b conjugate vaccine (polyribosylribitol
phosphate-tetanus toxoid conjugate). Clin Diagn Lab Immunol 8:1115-1119
45.
古泉ゆか, 服部裕美, 明田幸宏, 矢野秀美, 石和田稔彦, 一ノ瀬昭豊, et al.
2013. Hibワクチンによる免疫誘導能の評価とその臨床的意義：Hib vaccine
failure 例の解析. 病原微生物検出情報 (IASR) 34: 190-191
46.
武田薬品工業. 2014. 健康乳幼児におけるTAK-816の有効性及び安全性を検討
するアクトヒブを対照とした第Ⅲ相多施設共同無作為化二重盲検並行群間比較
31